DOI: 10.36347/sajb.2016.v04i08.002

Pages: 609-612

Coronary artery disease (CAD) is caused by atherosclerosis of the coronary arteries and is the leading cause of mortality and morbidity among patients with type 2 diabetes mellitus. Various types of markers have been used so far in order to reveal CAD and ischemia-modified albumin (IMA), also called cobalt binding albumin was reported as an early biomarker in cardiovascular disorders. The present study was conducted with an objective to evaluate the role of ischemia modified albumin in coronary artery disease with and without type 2 diabetes mellitus. A total of one hundred twenty (120) subjects (age group 25-70 years) of both sexes were enrolled in this study. The subjects were categorized into four groups i.e. Group I (30 normal healthy individuals), Group II (30 patients with diabetes mellitus with coronary artery disease), Group III (30 non-diabetic patients with coronary artery disease) and group IV (30 patients with diabetes mellitus without coronary artery disease). Serum ischemia modified albumin was estimated by albumin cobalt binding test using spectrophotometer. The mean serum level of IMA was increased in groups II and III and was statistically highly significant but it was significantly increased (but not highly significant) in group IV compared to that of control group. The level of IMA was increased in all the studied groups, so it may be used as a diagnostic marker of CAD. Also, as IMA is a marker of oxidative stress, antioxidants may be supplied to these patients so that they can counterbalance the oxidants.